Biogen Stock Explodes Higher After Alzheimer’s Drug Succeeds In Final-Phase Test

Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer’s plays with it — after its experimental treatment succeeded in a final-phase test.


The results are sorely needed for Biogen (BIIB), which has long struggled to target the neurological disease. In the Phase 3 study, the drug called lecanemab removed built-up plaque in the brain called beta amyloid. Importantly, this also led to a cognitive benefit for patients with an early-stage form of Alzheimer’s disease.

“We believe this should support a high likelihood for full approval, (Centers for Medicare and Medicaid Services) reimbursement and $8 billion in out-year worldwide end-user sales and should transform Biogen into an earnings growth story again starting in 2024,” RBC Capital Markets analyst Brian Abrahams said in a note to clients.

In response, Biogen stock rocketed 39.5% near 276 in morning trades on today’s stock market. Shares of Eisai, Biogen’s partner, soared more than 62% on the Frankfurt exchange.

The news helped boost Eli Lilly (LLY) which surged 7.4% near 334.20. Roche (RHHBY) stock also rose 4.8% near 40.90. Both companies are also testing Alzheimer’s drugs that cut down on beta amyloid levels in the brain.

Biogen Stock: Cognitive Benefit Confirmed

In the final-phase test, lecanemab not only cleared beta amyloid plaques in the brains of Alzheimer’s patients — a hallmark of the disease — but led to statistically significant benefits on cognition across the board, Biogen said in a news release.

It’s the latter point that sent Biogen stock skyward. The company has already shown its drugs can cut down on amyloid. Biogen gained accelerated approval last year for Aduhelm, a similar drug. But the benefits on cognition were dubious with one successful and one failed Phase 3 test.

For lecanemab, the results were “rather clean,” Mizuho Securities analyst Salim Syed said in a note. At 18 months, patients who received lecanemab showed a 27% slower decline in cognition compared with placebo recipients. This was measured by a scale known as the Clinical Dementia Rating-Sum of Boxes.

Other measures of cognition also turned up positive.

Also key for Biogen stock, just 12.5% of patients who received lecanemab experienced brain swelling known as amyloid-related imaging abnormalities, or ARIA. ARIA is a common side effect of amyloid-targeting drugs like lecanemab and Aduhelm. In the placebo group, 1.7% of patients had ARIA.

Reinvigorating The Alzheimer’s Space

SVB Securities analyst Marc Goodman says the results should be clinically meaningful for patients.

“We expect that these positive results will reinvigorate the Alzheimer’s disease space and increase the focus of the investor community for the two near-term anti-amyloid beta (drugs),” he said in a note. In that group, he counts Roche’s gantenerumab in the fourth quarter and Lilly’s donanemab in the first half of 2023.

He has an outperform rating on Biogen stock.

Biogen partner Eisai says it plans to file for approval in the U.S. before March.

Not every analyst is a believer, though. Needham’s Ami Fadia says the results are not the “slam dunk” needed to ensure Medicare authorities agree to cover lecanemab treatment. That’s the step that tripped Aduhelm.

“We believe it’s still too early to say for sure that lecanemab will be a multibillion-dollar opportunity, but this likelihood is certainly higher now,” she said in a note. She has a buy rating and 250 price target on Biogen stock.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


The Market Slumped Last Week; Why IBD Stock Of The Day Neurocrine Biosciences Didn’t

Cassava Plummets After Refuting New Claims Around Data Tampering Investigation

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Get Timely Buy & Sell Alerts With IBD Leaderboard

Find Today’s Best Growth Stocks To Watch With IBD 50